Your browser doesn't support javascript.
loading
[Current treatment strategies for follicular lymphoma]. / Aktuelle Therapiestrategien beim follikulären Lymphom.
Hiddemann, W; Hoster, E; Schmidt, C; Dreyling, M; Unterhalt, M.
Afiliação
  • Hiddemann W; Klinikum der Universität München, Campus Großhadern, Medizinische Klinik und Poliklinik III, Marchioninistr. 15, 81377, München, Deutschland. wolfgang.hiddemann@med.uni-muenchen.de.
  • Hoster E; Klinikum der Universität München, Campus Großhadern, Medizinische Klinik und Poliklinik III, Marchioninistr. 15, 81377, München, Deutschland.
  • Schmidt C; Klinikum der Universität München, Campus Großhadern, Medizinische Klinik und Poliklinik III, Marchioninistr. 15, 81377, München, Deutschland.
  • Dreyling M; Klinikum der Universität München, Campus Großhadern, Medizinische Klinik und Poliklinik III, Marchioninistr. 15, 81377, München, Deutschland.
  • Unterhalt M; Klinikum der Universität München, Campus Großhadern, Medizinische Klinik und Poliklinik III, Marchioninistr. 15, 81377, München, Deutschland.
Internist (Berl) ; 57(3): 222-9, 2016 Mar.
Article em De | MEDLINE | ID: mdl-26842683
ABSTRACT
In the last few years major changes have taken place in the management of follicular lymphoma (FL) leading to a substantial improvement in the prognosis of patients suffering from this disease. For patients with limited disease stages I and II radiotherapy can lead to long-term remission, while it still remains unclear whether this actually represents a cure; therefore, new approaches are investigating the combination of irradiation with an anti-CD20 antibody. For patients with advanced stages III and IV and a low tumor burden, watch and wait is still the first choice of management. For advanced stages III and IV and a high tumor burden, immunochemotherapy followed by 2 years of rituximab maintenance therapy is the worldwide accepted standard. New antibodies and new agents targeting oncogenic pathways or having immunomodulatory activity provide attractive new therapeutic options, which are currently being explored in clinical phase II/III studies. These approaches provide the perspective to establish chemotherapy-free therapy concepts in the near future.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Linfoma Folicular / Terapia de Alvo Molecular / Quimiorradioterapia / Rituximab / Imunoterapia Limite: Humans Idioma: De Ano de publicação: 2016 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Linfoma Folicular / Terapia de Alvo Molecular / Quimiorradioterapia / Rituximab / Imunoterapia Limite: Humans Idioma: De Ano de publicação: 2016 Tipo de documento: Article